Fundraising FoxOSAKA University Venture Capital
Corporate VCOsaka · Pre-Seed–Growth · 20 people tracked
Also known as 大阪大学ベンチャーキャピタル株式会社
Find your way into OSAKA University Venture Capital
Sign up to see every warm intro you have to OSAKA University Venture Capital
- Paths you didn't know you had: your email and LinkedIn already hold routes to the OSAKA University Venture Capital team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
OUVC operates under Osaka University's vision of being a world-leading innovative university that contributes to social transformation. The firm aims to translate university research results into real-world applications and back ventures born from Osaka University's research seeds, supporting their commercialization to help build a prosperous future society. Its activity spans areas such as life sciences and deep-tech research spinouts, including support for university-originated seeds in fields like sulfur polymers, heart failure treatments, and osteoporosis treatment devices.
Source: firm website, verified Aug 3, 2026.
Team · 20 people
from the firm's website
What they invest in
from 44 of 88 portfolio companiesMedical Devices ×23Biotech ×21Deep Tech ×21Healthtech ×21AI & Machine Learning ×13Digital Health ×10Cleantech ×6Hardware ×6
HQs:Japan×39United States×2
Who they back
founder profiles across 21 portfolio companiesFounding team size:solo founder×112 founders×43 founders×34+ founders×3
Investments · 88 tracked
founders shown can be your intro pathmediVR is a medical device manufacturer founded in 2016 that develops VR-based rehabilitation solutions for stroke and other neurological conditions.
Digital HealthHealthtechMedical Devices豊中市, JP
原正彦(代表取締役)in村川雄一朗岡田拓己横川堅太塩澤亜紀青木武士
Co-investorsDBJ Capital
A-SEEDS is a Shinshu University spin-out developing non-viral gene-modified immune cell therapies, including non-viral CAR-T cell products, to treat pediatric and young-adult cancers, including solid tumors, that lack effective treatments.
BiotechDeep TechHealthtechMedical DevicesMatsumoto, JP
Yozo Nakazawa(Founder & Director; Professor, Department of Pediatrics, Shinshu University)Shigeki Yagyu(Representative Director (CEO))inTakuji Achiha(Chief Development Officer)Kiyohito Tani(Chief Operating Officer)
Co-investorsDelight VenturesNippon Venture Capital
A-wave develops medical devices and related software/hardware products for healthcare applications.
AI & Machine LearningHealthtechMedical Devices大阪市, JP
Co-investorsGlobal BrainJapan Post Insurance NEXT Partners
AIBTRUST is a University of Osaka-originated venture company based in Japan working in the artificial intelligence field.
AI & Machine LearningData & InfrastructureDigital HealthTokyo, JP
森岡 康一(代表取締役 (Representative Director))
A Thai-language online slots website that aggregates various online slot games, including PG Slot titles, accessible through web browsers on mobile, tablet, and desktop.
ConsumerGaming
Bioworks develops PlaX, a plant-based fiber intended as an alternative to petroleum-derived synthetic fibers, aimed at making the apparel industry more sustainable.
BiotechCircular EconomyNew Materials未記載, JP
今井 行弘(取締役会長 (Founder))坂本 孝治(代表取締役社長 CEO)寺田 貴彦(取締役常務執行役員 CTO)
Co-investorsGOLDWIN VENTURE PARTNERS
Celaid Therapeutics develops hematopoietic stem cell expansion technology, including a method to replace albumin with polyvinyl alcohol and to expand human hematopoietic stem cells ex vivo in large quantities.
BiotechDeep TechHealthtechMedical Devices
Nobuyuki Arakawa(Co-founder & Representative Director, President & CEO)inMotoo Watanabe(Co-founder / Advisor (former Chairman & CSO))inHiromitsu Nakauchi(Co-founder)Masatoshi Sakurai(Co-founder)Yusuke Inoue(Director, COO & CFO)inAsako Uchiyama(Director, CDO (Chief Development Officer))in
Co-investorsKobe University CapitalUTEC
Crimson Technology is a Japanese company involved in music-related technology, including audio and AI music, with affiliations to Japanese music electronics and metadata industry bodies.
AI & Machine LearningCreator EconomyMedia & EntertainmentTokyo, JP
Kazuo Higa(代表取締役 (Representative Director))
EX-Fusion is a Japanese private company developing laser-based nuclear fusion energy technology, aiming to decarbonize existing energy sources and contribute to carbon neutrality.
CleantechDeep TechEnergyKyoto, JP
Kazuki Matsuo(Founder)inShinsuke Fujioka(Founder)Yoshitaka Mori(Founder)
Co-investorsChishima Real Estate — Startup InvestmentDelight VenturesMiyako CapitalMPowerShizuoka Capital
GAIA BioMedicine (株式会社ガイアバイオメディシン) develops GAIA-NK, a cell therapy using engineered cells with high cytotoxic activity against solid tumors, based on research from Kyushu University.
BiotechHealthtechMedical DevicesFukuoka, JP
Yoshikazu Yonemitsu(Founder)Kazuyuki Kuramori(Representative Director, President & CEO)inYui Harada(Director & CTO)Daisuke Ara(Director & CFO)
Co-investorsJIC Venture Growth InvestmentsUntroD Capital
HOIST is an Osaka University-derived biotech venture developing anti-cancer drugs, focusing on novel modalities and mechanisms of action for cancers that lack sufficient treatments.
BiotechDigital HealthHealthtechMedical DevicesWakayama, JP
柿沼千早(代表取締役 (CEO))
HULIX is an Osaka University spinout building 3D spatial AI that uses LiDAR, SLAM, 3D point cloud analysis, and digital twin technology to convert real-world spaces into AI-usable data.
AI & Machine LearningData & InfrastructureDeep TechIoTSuita, JP
Mitsuo Moriya(Representative Director & CEO)
BoardHiromi Yamaguchi(Director)
J-Tec develops, manufactures, and sells high-precision X-ray mirrors ("OsakaMirror") and other optical elements based on ultra-precision machining and metrology, along with ultra-precision polishing equipment for Si, SiC, diamond, and ceramic wafers.
Advanced ManufacturingDeep TechHardwareSemiconductorsOsaka, JP
JEPLAN is a Japanese group focused on recycling and circular economy, working with domestic and international partners under the mission of "circulating all things." It aims to advance a circular economy through recycling technologies and operations across its business sites and factories.
Circular EconomyCleantechClimate TechNew MaterialsTokyo, JP
髙尾 正樹(代表取締役 執行役員社長 (President & CEO))
Co-investorsGOLDWIN VENTURE PARTNERSRakuten CapitalShizuoka CapitalUntroD CapitalJAFCO GroupUniversal Materials Incubator
KOTAI Biotechnologies develops an immune AI platform and big data analysis pipeline that combines artificial intelligence with immunology for antibody and immune-repertoire analysis.
AI & Machine LearningBiotechDeep TechDigital HealthHealthtechMinoh, JP
山下 和男(共同創業者・代表取締役 (Co-founder & CEO))Kazuo Yamashita(Co-founder & CEO)
LQUOM develops long-distance quantum communication technology and quantum repeaters to enable theoretically unhackable quantum internet for sectors including finance, telemedicine, and defense.
CybersecurityDeep TechQuantum ComputingYokohama, JP
Kazuya Niizeki(Co-founder & CEO)inTomoyuki Horikiri(Co-founder & CSO, Director)in
Co-investorsMPower
Metcela is a Japanese biotech company developing science-backed therapies for pediatric and rare diseases, with in-house capabilities spanning research through development.
BiotechHealthtechMedical Devices
Co-investorsBeyond Next VenturesF-Prime CapitalSony Ventures CorporationTOHOKU University Venture PartnersUTEC
MiCAN Technologies produces immortalized blood cells (erythroid and myeloid-lineage cells) using regenerative medicine technology, supplying research-use blood-like cells, evaluation kits, and contract testing services.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesKyoto, JP
Kazuo Miyazaki(代表取締役CEO (Representative Director & CEO))inKazuhisa Fushihara(取締役CFO (Director & CFO))in
BoardYasuhiro Natsume(取締役 (Director))
Co-investorsKobe University CapitalUntroD Capital
MyImmune develops AI that analyzes adaptive immune repertoire data to identify drug targets, predict patient responses to immunotherapies, and build biomarkers and companion diagnostics.
AI & Machine LearningBiotechDigital Health
Ayan Sengupta(Founder)in
PaMeLa develops compact, low-burden medical devices that use artificial intelligence to objectively measure and visualize pain, addressing the reliance on patients' subjective self-reporting.
AI & Machine LearningDigital HealthHealthtechMedical DevicesOsaka, JP
後藤 宏明(代表取締役 (Representative Director))
Co-investorsUniversal Materials Incubator
Red Arrow Therapeutics develops cancer therapies using a proprietary nanopolymer drug-delivery system for programmable encapsulation and release of biologics such as peptides, antibodies, and proteins.
BiotechHealthtechMedical DevicesCambridge, US
Horacio Cabral(Scientific Founder / Technology Pioneer)Philipp Steiner(Chief Scientific Officer (CSO))
Co-investorsBeyond Next VenturesKeio Innovation InitiativeUTEC
RegCell Biosciences is a biotechnology company developing regenerative cell therapies, leveraging expertise in cell and gene therapy, manufacturing, and immunology to advance therapeutic treatments.
BiotechDeep TechMedical Devices
Michael McCullar, PhD(Chief Executive Officer)James Ahlers(Chief Financial Officer)Marty Giedlin, PhD(Chief Technology Officer)Tony Hurley(Chief Technical Operations Officer)Steve Kanner, PhD(Chief Scientific Officer)
Co-investorsFast Track InitiativeGlobal BrainKyoto University Innovation CapitalUTECMitsubishi UFJ Capital
Restore Vis is a life sciences company founded by a vitreoretinal surgeon and clinician scientist focused on addressing inflammation, aging, neurodegeneration and angiogenesis through translational research from drug discovery to clinical trials.
BiotechDigital HealthHealthtechMedical DevicesTokyo, JP
Dr. Rajendra S. Apte(Paul A. Cibis Distinguished Professor; Vice Chair of Innovation and Translation; Founder)Yusaku Katada MD, PhD(Co-founder, Representative Director and CEO/CMO)Hikaru Miyazaki(Representative Director and COO)in
Co-investorsAstellas Venture Management LLCDBJ CapitalJIC Venture Growth InvestmentsKyoto University Innovation CapitalNippon Venture CapitalRemiges Ventures, Inc.+3 more
Revascular Bio develops cell therapy treatments using vascular endothelial stem cells to address diseases caused by vascular dysfunction, including chronic wounds, severe limb ischemia, and genetic blood disorders.
BiotechDeep TechMedical DevicesSuita, JP
Shinsei Omori(Representative Director, President & CEO)
Company that produces complex ceramic components using a stereolithography (slurry-based) 3D printing process, in which ceramic powder is mixed with UV-curable resin, shaped layer by layer with a UV laser, then debinded and sintered.
Advanced ManufacturingHardwareNew MaterialsKusatsu, JP
Tadakatsu Asano(Representative Director & President)
TCN Prime develops medical devices for cardiovascular applications, including innovative catheter systems for treating aortic stenosis and ECMO support.
Deep TechHealthtechMedical DevicesTokyo, JP
小西明英(CEO / Representative Director)岩崎正道(Director / CMO)八木隆浩(Director / CTO)三池信也(Director / CFO)
Co-investorsKobe University Capital
Alpha Fusion is a Japanese biotechnology company developing targeted alpha therapy drugs based on Astatine-211 (211At) to treat cancer with reduced side effects to healthy tissue.
BiotechDigital Health
Co-investorsGlobal BrainKobe University Capital
IMMUNOSENS manufactures in vitro diagnostic pharmaceuticals and third-class medical devices for clinical diagnostic purposes.
BiotechHealthtechMedical Devices
Co-investorsGlobal Brain
Kringle Pharma develops and manufactures HGF protein-based pharmaceuticals for treating conditions including spinal cord injury, ALS, and vocal cord scarring.
BiotechDeep TechHealthtechMedical DevicesOsaka, JP
Toshikazu Nakamura安達喜一
Co-investorsChishima Real Estate — Startup InvestmentDBJ CapitalTOHOKU University Venture Partners
J-Pharma is a drug development company focused on SLC transporter-targeted therapies, with its lead LAT1 inhibitor nanvuranlat (JPH203) in a global Phase 3 trial for biliary tract cancer and other candidates addressing cancer, autoimmune, and rare diseases.
BiotechDigital HealthHealthtechMedical DevicesTokyo, JP
𠮷武 益広(代表取締役社長 (Representative Director & President))藤本 裕(取締役CFO)山本 寛(取締役CBO)
Co-investorsF-Prime CapitalKSP, Inc.Newton BiocapitalOita Venture CapitalSeibu Shinkin CapitalUntroD Capital
ThinkCyte develops diagnostic devices and cellular analysis platforms using imaging flow cytometry and microfluidics technology.
AI & Machine LearningBiotechDeep TechMedical DevicesRedwood City, US
Waichiro(Co-founder & CEO)Sadao(Co-founder & CSO)Issei(Co-founder & Senior Scientific Advisor)Ryoichi(Co-founder)
Co-investorsBerkeley SkyDeck FundGlobal BrainMitsui Sumitomo Insurance CapitalUntroD Capital
Toregem Biopharma is a Kyoto University spin-off developing a tooth-regeneration drug based on a humanized anti-USAG-1 antibody that aims to regrow teeth with a single injection.
BiotechDeep TechHealthtechMedical Devices京都 (Kyoto), JP
喜早 ほのか (Honoka Kihayashi)(代表取締役社長 (Representative Director and President))髙橋 克 (Katsu Takahashi)(取締役CTO (Director and CTO))髙谷 宗男 (Muneo Takaya)(取締役CBO (Director and CBO))喜早 ほのか(Co-founder & CEO (代表取締役社長))髙橋 克(Co-founder & CTO)髙谷 宗男(Co-founder & CBO)
Co-investorsAstellas Venture Management LLCKyoto University Innovation CapitalTOHOKU University Venture Partners
Nanomist Technologies develops, manufactures, and sells atomization-separation systems that separate and purify solutions without heat or pressure, along with related equipment for wastewater purification, hot-spring concentration, VOC recovery, and fine-powder production.
Advanced ManufacturingCleantechDeep TechHardware
Kazuo Matsuura(代表取締役社長 (President & CEO))
Co-investorsIyogin Capital
NexFi Technology Inc. develops, manufactures, and sells high-voltage power equipment using next-generation SiC (silicon carbide) power devices.
CleantechDeep TechEnergyHardwareSemiconductorsOsaka, JP
Takashi Nakamura(代表取締役社長 (President & CEO))
Co-investorsTEL Venture Capital, Inc.
A company developing microwave-based chemical processing technology to improve energy efficiency and reduce carbon emissions in the chemical manufacturing industry.
Advanced ManufacturingCleantechClimate TechDeep TechNew Materials吹田市, JP
塚原 保徳(代表取締役CSO（最高科学責任者）)Iwao Yoshino(Representative Director CEO)inYasunori Tsukahara(Representative Director CSO)吉野 巌(代表取締役社長CEO)
Co-investorsINCJ, Ltd.Chishima Real Estate — Startup InvestmentDBJ CapitalJAFCO GroupSMBC Venture CapitalUTEC
Luxna Biotech develops nucleic acid medicines (oligonucleotide/antisense therapeutics) based on bridged/crosslinked modified nucleic acid chemistry originally developed at Osaka University.
BiotechDeep Tech
Co-investorsKobe University CapitalTOHOKU University Venture Partners
3DC develops Graphene MesoSponge (GMS), a three-dimensional carbon material invented at Tohoku University, and advanced electrode manufacturing technologies to improve battery performance.
CleantechDeep TechNew MaterialsSendai, JP
Takuma Kuroda(Co-Founder & CEO)inHirotomo Nishihara(Co-Founder & CSO)
Co-investorsSony Ventures CorporationUntroD Capital
AFI manufactures rapid microbial detection systems using flow cytometry and solid-phase cytometry technologies for quality control in pharmaceuticals, clinical diagnostics, cosmetics, food and beverage, and environmental testing.
HardwareHealthtechMedical DevicesTokyo, JP
Co-investorsKyoto University Innovation Capital
Japanese company developing AI-based patent examination and intellectual property analysis software, including its "AI Samurai" patent similarity evaluation and search systems used for patent research and IP landscape analysis.
AI & Machine LearningEnterprise SoftwareLegalTechSaaSOsaka, JP
Co-investorsKiraboshi CapitalSeibu Shinkin Capital
Ayumo develops a gait analysis device designed by orthopedic physicians to support people with walking difficulties in receiving early appropriate treatment and improving motor function.
AI & Machine LearningHealthtechMedical Devices
Orbital Lasers develops space optical technology centered on satellite lasers, including systems aimed at addressing space debris, satellite bus, and mission instrument development.
Deep TechHardwareSpace TechTokyo, JP
Tadanori Fukushima(Representative Director & CEO)inYoshiyuki Muramatsu(Director & CFO)Teppei Kato(Executive Officer, CBO (Chief Business Officer))inMasayuki Maruyama(CLTO (Chief Laser Technology Officer))in
Co-investorsAngel Bridge Co.,Ltd.JIC Venture Growth InvestmentsKeio Innovation InitiativeUTokyo Innovation Platform Co. Ltd.
PURMX Therapeutics develops nucleic acid medicines as anti-cancer drugs based on microRNA research and the concept of an "ageing switch" to induce ageing in cancer cells.
BiotechHealthtechLongevityMedical DevicesHiroshima, JP
Hidetoshi Tahara(CEO/Representative Director and President)in
Co-investorsHiroshima Venture Capital Co. Ltd.Keio Innovation InitiativeUTEC
QunaSys develops algorithms and software to maximize the performance of quantum computers, aiming to make quantum computing practical for real business applications.
AI & Machine LearningDeep TechQuantum ComputingSaaSTokyo, JP
楊 天任 (Tennin Yang)(Co-founder & CEO)御手洗 光祐 (Kosuke Mitarai)(Co-founder & Advisor)Tennin Yan(代表取締役 (CEO / President))in松岡 智代(COO)越智 由浩(CRO)Erik Stangerup(QunaSys Europe CEO)in
Co-investorsFujitsu VenturesGlobal BrainJIC Venture Growth InvestmentsKDDI Open Innovation FundMirai Creation Fund
Ai-BrainScience Inc. is a Japanese company holding a Type 2 medical device manufacturing and sales license.
AI & Machine LearningDigital HealthHealthtechMedical DevicesSuita, JP
森下 竜一(取締役会長 (Chairman))髙村 健太郎(代表取締役社長 (President & CEO))
Board北嶋 学(取締役 (Director))
Co-investorsMiyako CapitalNippon Venture Capital
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
㈱糖鎖工学研究所C4U株式会社CotobadesignHuLA immune株式会社ImmunorockNanophotonPaMeLa株式会社PGV株式会社アイポア株式会社アルファフュージョン株式会社クリムゾンテクノロジー 株式会社クリングルファーマ株式会社シンクサイト株式会社セレイドセラピューティクス株式会社ナノフォトン株式会社ネクスファイ・テクノロジー株式会社パイクリスタル株式会社ペリオセラピア株式会社マイキャン・テクノロジーズ 株式会社リバスキュラーバイオ株式会社レグセル株式会社株式会社 ジェイテックコーポレーション株式会社HULIX株式会社JiMED株式会社SENTAN Pharma株式会社TCNプライム株式会社Thinker株式会社イムノセンス株式会社イムノロック株式会社エスケーファイン株式会社エルブズ株式会社ガイアバイオメディシン株式会社コトバデザイン株式会社サイキンソー株式会社テレノイドケア株式会社ファンペップ株式会社マトリクソーム株式会社メディタクト株式会社メトセラ株式会社リモハブ株式会社レストアビジョン株式会社糖鎖工学研究所
Frequently asked questions
- How many investments has OSAKA University Venture Capital made?
- OSAKA University Venture Capital has 88 tracked investments, including 1 dated in the last 24 months.
- What stage does OSAKA University Venture Capital invest at?
- OSAKA University Venture Capital invests at the Pre-Seed, Seed, Series A, Growth stages.
- What sectors does OSAKA University Venture Capital focus on?
- OSAKA University Venture Capital focuses on Advanced Manufacturing, Biotech, Deep Tech, Healthtech, Medical Devices, Sector Agnostic.
- Where is OSAKA University Venture Capital located?
- OSAKA University Venture Capital is headquartered in Osaka, JP.
- Who does OSAKA University Venture Capital co-invest with?
- OSAKA University Venture Capital most often shares deals with Kobe University Capital, UntroD Capital, DBJ Capital, among 44 tracked co-investors.
Images
Similar investors
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Khosla Ventures is a venture capital firm that backs bold, early-stage, technology-driven companies across deep tech and other sectors, providing hands-on 'venture assistance' to help founders build category-defining businesses.
Artesian is a deep tech and hardware venture capital investor that builds funds around specific institutional backers — governments, corporations, universities, industry bodies and super funds — to pursue both financial returns and strategic outcomes in critical industries.
A globally recognized venture capital firm designed to provide access to highly competitive venture deals to individual investors, consistently recognized for top-decile DPI performance and as one of the most active US venture firms.
Clarendon Fund Managers is a Belfast-based venture capital fund manager, regulated by the FCA, that manages regional VC funds in Northern Ireland and provides equity finance to growth-focused businesses.